Postpartum Hemorrhage (PPH) Treatment Devices Market

Postpartum Hemorrhage (PPH) Treatment Devices Market Outlook (2022-2026)

As per a new Fact.MR analysis, the global postpartum hemorrhage (PPH) treatment devices market is set to enjoy a valuation of US$ 777 million in 2022 and further expand at a CAGR of 4% to reach US$ 909 million by the end of 2026.

Uterine balloon tamponade technologies are expected to attain a valuation of US$ 428 million by 2026.

Report Attributes	Details
Postpartum Hemorrhage Treatment Devices Market Size (2022E)	US$ 777 Million
Forecasted Market Value (2026F)	US$ 909 Million
Global Market Growth Rate (2022-2026)	4% CAGR
U.S. Market Value (2022)	US$ 278 Million
China Market Value (2026)	US$ 115 Million
Key Companies Profiled	3RD Stone Design, Inc. Bactiguard AB Becton, Dickinson, and Company C. R. Bard, Inc. Cook Medical, Inc. Alydia Health Revmedx Inc. Teleflex Incorporated Utah Medical Products, Inc.

Postpartum Hemorrhage Treatment Device Demand Analysis (2017-2021) Vs. Market Forecasts (2022-2026)

Severe vaginal bleeding following childbirth is known as postpartum hemorrhage (PPH). It's a critical condition that may be fatal. The symptoms of postpartum hemorrhage also include fainting, dizziness, and blurred vision. PPH can develop up to 12 weeks postpartum or after birth. A complete recovery is possible with early discovery and prompt treatment.

Postpartum hemorrhage is defined as bleeding that is severe enough to result in symptoms of excessive blood loss or a significant change in heart rate or blood pressure following birth, regardless of whether it was a vaginal delivery or a Cesarean section, or a C-section.

There are two different types of postpartum hemorrhage. Within the first 24 hours following delivery, there is a primary postpartum hemorrhage. From 24 hours to 12 weeks after delivery, there may be a late or secondary postpartum hemorrhage. Although there are multiple PPH risk factors, over 40% of hemorrhages in women happen without any known risk factors. The majority of postpartum bleeding happens immediately after placenta delivery.

The four common causes of postpartum hemorrhage are uterine atony, uterine trauma, retained placental tissue, and blood clotting condition. The diagnosis of postpartum hemorrhage is made by medical professionals through visual and physical examinations, blood tests, and a careful study of medical history.

Medical professionals handle PPH as an emergency. The objectives of treating postpartum hemorrhage are replenishing blood volume and halting the source of the bleeding as quickly as feasible.

Most maternal morbidity and mortality worldwide are caused by postpartum hemorrhage. When compared to industrialized nations, emerging economies are responsible for a noticeably larger number of obstetric haemorrhage fatalities.

Growing instances of pregnancy-related difficulties, such as multiple pregnancies and inverted uteruses, which significantly raise the risk of postpartum bleeding or hemorrhage, are expected to fuel demand for PPH treatment devices.

The global postpartum hemorrhage treatment devices market is currently valued at around US$ 777 million and is anticipated to progress at a CAGR of 4% through 2026, says Fact.MR, a market research and competitive intelligence provider.

Which Opportunities Await Postpartum Hemorrhage Treatment Device Suppliers?

“Rising Pregnancy-related Issues & Technological Advancements to Provide Comfortable Products are Trends Liable for Postpartum Hemorrhage Treatment Devices Market Growth”

Rising occurrence of pregnancy-related issues, such as large-for-baby births, inverted uterus, and multiple pregnancies, among others, is one of the major factors propelling the growth of the global postpartum hemorrhage treatment devices market. 4t postpartum hemorrhage is the name given to the causes of postpartum hemorrhage (tone, trauma, tissue, and thrombin).

Also, increased postpartum hemorrhage risk factors in pregnant women such as increasing anaemia instances, trauma, and uterine atony, are significant drivers in the growth of the global market for postpartum hemorrhage treatment products.

The necessity for cutting-edge treatments and equipment to provide efficient treatment for pregnancy-related problems has increased as cases of maternal fatalities rise. The market for postpartum hemorrhage treatment systems is anticipated to see a significant increase in demand as a result of these factors.

Also, the market for postpartum hemorrhage treatment devices is lucrative in rich countries. Within the projection period, the huge increase in technologically enhanced products to improve comfort levels may create new opportunities.

Which Factors are Expected to Adversely Downgrade Postpartum Hemorrhage Devices Market Size?

“High Cost of Some Systems Not be Affordable by Every Clinic, Which Impedes PPH Treatment Devices Market Growth”

Factors including expensive goods, lack of consumer awareness, and shortage of qualified personnel limit market expansion. The market has significant challenges that could have a detrimental effect on its development, including a strict regulatory environment and the deleterious impacts of some gadgets.

Which Regions are Lucrative for Manufacturers of PPH Treatment Devices?

“Advanced Healthcare Infrastructure & Rising Cases Related to PPH Driving Sales of Postpartum Hemorrhage Treatment Products in North America”

Regionally, North America is expected to have a stronghold on the market for PPH treatment devices. The main drivers of demand from the North America PPH treatment devices market are the rising cases of PPH in the region, increasing patient and healthcare provider awareness, high hospital delivery rates, and the commercial availability of treatment devices.

PPH treatment device manufacturers have noticed profitable potential in countries such as the United States, Canada, and Mexico. These nations have advanced healthcare systems, which supports the growth of the PPH treatment devices market in the region.

In terms of revenue contribution to the market for PPH treatment devices worldwide, Europe is expected to lag behind North America.

Due to an increase in the number of women with anaemia in the Asia Pacific region, which in turn raises the risk of PPH, Asia Pacific is anticipated to see the largest CAGR between 2022 and 2026. Furthermore, growing public awareness of PPH problems and rising healthcare costs are giving key manufacturers a potential postpartum hemorrhage devices market opportunity.

Country-wise Analysis

How is the Market for PPH Treatment Devices Developing in the U.S.?

“Advancements in Postpartum Hemorrhage Treatment Technologies to Reduce Pregnancy Mortality Rate in U.S.”

The United States market for postpartum hemorrhage treatment devices is currently valued at US$ 278 million.

Rising rates of maternal mortality and pregnancy-related problems are expected to fuel market expansion in the United States. The availability of advanced healthcare facilities, rising awareness, simple access to treatment equipment, and high hospital delivery rates are all factors that will benefit the market.

Postpartum hemorrhage cases are increasing and are now reported in more than 100,000 pregnancies annually, or around 3 percent of deliveries in the United States. These are concerning figures, especially because postpartum hemorrhage is a major factor in pregnancy-related fatalities.

• According to a new CDC Foundation study, hospitals may be able to save up to 70% of obstetric deaths related to hemorrhages.

Why is Germany Exhibiting High Sales of PPH Treatment Devices?

“Favourable Government Policies & High Risk of PPH to Boost Postpartum Hemorrhage Treatment System Sales”

The market for postpartum hemorrhage treatment devices in Germany is expected to expand at a CAGR of 3% from 2022 to 2026.

Due to a sizable population at risk for illnesses such as severe PPH, numerous pregnancies, uterine fibromas, HELLP syndrome, and anaemia, the Germany market is anticipated to have enormous expansion. The market is fueled by the government's backing for the industry's current players as well as the rising frequency of these issues.

Category-wise Analysis

Which PPH Product Type is Enjoying High Demand?

“Easy to Use & Effective Results Make Uterine Balloon Tamponades Prominent Choice for PPH Treatment”

Uterine balloon tamponades are currently in very high demand in the market among the numerous products offered. They are easy to use, extremely effective, and readily available in the marketplace.

Thus, uterine balloon tamponades have become the market's leading product category. Uterine balloon tamponade sales are expected to expand at a CAGR of 4% from 2022 to 2026.

However, compared to other products in the market, sales of uniject prefilled injectable systems are expected to increase more quickly. Uniject is a disposable injectable system that automatically deactivates.

Due to the straightforward application of uniject prefilled injection systems, their reasonable cost, and the growing involvement of government organisations in encouraging their use, the product segment is anticipated to experience significantly increased demand throughout the projected period.

Intramuscular (IM) injections or an all-in-one auto-disposable drug delivery system for subcutaneous is the uniject prefilled injection system. With the help of this technology, it is possible to fill a specific medicinal dose in a single quantity precisely, guaranteeing the delivery of the right dosage and preventing needless dose disposal.

By combining the syringe and the medicine into a single unit, this technology reduces the load on the healthcare system. In addition, the use of non-pneumatic anti-shock garments (NASG) is also expected to expand dramatically in the coming next 4 years.

Competitive Landscape

Top companies in the postpartum hemorrhage devices market are emphasizing organic growth initiatives, including new system launches, product approvals, and patents and promotions through events.

Collaborations, acquisitions, and partnerships are examples of inorganic growth tactics in the market. These actions have made it possible for market participants to grow their consumer bases and operations across regions.

• On August 9, 2022, BD (Becton, Dickinson and Company), a top global medical technology company, and Labcorp, a renowned life sciences company, announced a collaboration agreement. This framework will be used to develop, produce, market, and sell flow cytometry-based companion diagnostics (CDx).

Segments of Postpartum Hemorrhage Treatment Devices Industry Research

• By Product :

  • Uterine Balloon Tamponades
  • Non-pneumatic Anti-shock Garments (NASG)
  • Uniject Prefilled Injection Systems

• By End User :

  • Hospitals
  • Clinics
  • Others

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • MEA